NEW ORLEANS – Each year, more than 100,000 patients in the U.S. undergo implantation of a new implantable cardioverter defibrillator (ICD) for heart rhythm abnormalities. This number constitutes a 20-fold increase over the last 15 years. Current medical guidelines advocate discussion of end of life care of these medical devices, including deactivation, but many patients may not understand their options. Now, researchers at the University of Pennsylvania School of Medicine say that discussions should also address post-mortem donation of ICDs for product improvement or reuse overseas as pacemakers, to help reduce global health disparities.
“ICD patients agree that discussions about ICDs and end of life are important,” said senior author James Kirkpatrick, MD, assistant professor of Medicine, Cardiovascular Medicine Division at Penn. “The majority of the patients we polled also support the concept of an ICD-specific advanced-directive (AD) and post-mortem donation for product improvement or reuse, but have not considered or discussed these topics."
Penn researchers conducted a phone survey of 153 ICD patients concerning advance directives and ICD handling at the end of life. Half of the patients that were questioned said they would like their ICD deactivated in an end of life illness. Most also thought that a do not resuscitate (DNR) order justified ICD deactivation. Although 17 percent reported ever thinking about ICDs in an end of life illness; just two patients had actually addressed the topic in an advance directive arrangement. Only five percent of the patients had ever discussed ICD deactivation directly with their doctor.
Regarding donation of ICDs for reuse or review of the device for improvement purposes, 88 percent said they would donate their device to facilitate product improvement, 87 percent would donate for reuse overseas, and 80 percent for reuse in animals. When asked to choose just one donation option, the majority of patients would donate their devices for reuse in patients overseas. The study results were reported at the 2011 American College of Cardiology meeting in New Orleans.
Dr. Kirkpatrick and colleagues at Penn concluded "Educational initiatives aimed at patients and their families are warranted to help cardiovascular clinicians address end of life issues.”
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.